ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
Learn With ETMarkets: Can retail SIPs replace FII flows as India’s market backbone?
Systematic Investment Plans (SIPs) reached an all-time high of ₹27,269 crore in June 2025, reinforcing retail investor confidence and providing liquidity support amid foreign outflows.